Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 16 ... reported license revenue of $2.4 million, a portion of the $110 million received from Biogen Idec for the collaboration agreement entered into on June 30, 2009. The balance of this ...
2009 NOV 16 ... from Novartis, the National Institutes of Health (NIH), Cubist Pharmaceuticals, Inc., Biogen Idec Inc., InterfeRx™, research reagent and services licensees, and other sources. ...
2009 NOV 23 ... 13, 2009 at 8:30 a.m. MST, 6:30 a.m. EST.). The corrected release reads: BIOGEN IDEC TO PRESENT AT THE 2009 ANNUAL CREDIT SUISSE HEALTHCARE CONFERENCE...
2009 NOV 16 ... Amgen and Biogen both saw their share values drop 10 and 16 percent respectively. Biogen Idec's shares were hit following reports that the number of cases of a rare brain infection ...
2009 NOV 16 ... Caliper invited pioneers in this field from Pfizer (PFE), Amgen (AMGN), and Biogen Idec (BIIB) to describe their analytical approaches for biologics characterization. These ...
2009 NOV 2 ... Inc. a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq:BIIB) announced that the companies received a Complete Response from the U.S. ...
2009 NOV 23 ... with Genentech (a wholly-owned member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. The most advanced compound, trastuzumab-DM1 (T-DM1), is in Phase III ...
2009 NOV 9 ... actively developing at least one TAP compound now include: Amgen, Bayer HealthCare, Biogen Idec, Biotest, Genentech/Roche and sanofi-aventis as well as ImmunoGen. In ...
2009 NOV 1 ... and offices. New Clients Over the past 12 months, Instem's new clients include Biogen Idec, Cubist Pharmaceuticals, LPT Pharma, RTI International, the University of Southern ...
2009 NOV 16 ... of surveyed MCOs expect to cover its competitors, Genmab/GlaxoSmithKline's Arzerra and Biogen Idec/Roche's ocrelizumab, respectively. The Rheumatoid Arthritis Biologics ...
2009 NOV 23 ... life-sciences sectors. For more information, please visit www.ca-privateequity.com About Biogen Idec New Ventures:New Ventures is Biogen Idec's corporate ...
2009 NOV 16 ... with MabThera have been recorded worldwide since its launch. Genentech and Biogen Idec co-market Rituxan in the United States, and Roche markets MabThera in the rest of the ...
2009 NOV 2 ... a worldwide development and marketing agreement for lead product lixivaptan with Biogen Idec. "The new company assembled by this investor syndicate includes an ...
Subject: Unigene Laboratories, Inc. / Tarsa Therapeutics, Inc.
2009 NOV 9 ... Osage Partners and previous investors: Clarus Ventures, Venrock, MedImmune Ventures and Biogen Idec New Ventures. The new funds bring the Series A total since January 2008 up to $47.75 ...
